Board of directors

Chair, board member since 2024; chair of the Compensation & benefits committee, and the Transaction committee; member of the Scientific committee.

Born 1963; American national.

Education: Bachelor of Arts (Management) from the University of Cincinnati, USA.

Other assignments: CEO of Genetix Biotherapeutics Inc, member of the Board of Directors of Cullinan Therapeutics, uniQure (chair), and the University of Southern California School of Pharmacy and Pharmaceutical Sciences.

Prior experience: CEO and Board Director of Mirati Therapeutics Inc, FerGene Inc, and Ipsen SA. Senior executive positions at Baxalta Inc, Endocyte Inc, Novartis Pharmaceuticals, and Johnson & Johnson.

Independent of Sobi and its executive management: Yes

Independent in relation to major shareholders of Sobi: Yes

Shares in Sobi: 3,843.

Board member since 2023; member of the Compensation & benefits committee.

Born 1970; French and German national.

Education: Master of Business Administration from the International Institute for Management Business School, Switzerland and Bachelor of Arts from ISG Business School, France.

Other assignments: CEO of Leo Pharma A/S.

Prior experience: CEO of Orphazyme A/S. Senior Vice President, General Manager, US Oncology Business and member of the Operating Team at Amgen Inc. Senior Vice President of Europe, Middle East, Africa and Canada at Alexion. Other key roles within the international pharmaceutical industry.

Independent of Sobi and its executive management: Yes

Independent in relation to major shareholders of Sobi: Yes

Shares in Sobi: 0.

Synthetic shares: 929.

Board member since 2026; member of the Audit committee, and the Scientific committee.

Born 1958; Swedish and American national.

Education: MD and PhD in tumour immunology and Visiting Professorship from the University of Lund, Sweden. 

Other assignments: Chair of the Board of BenchSci. Board member of Agilent Technologies, Apellis Pharmaceuticals, ChAI discovery, Element Biosciences Inc, Enveda 6(19) Bio, Fair Journey Bio, ImmuneAi, Orbis Medicines, QuantumCell ApS, Quarry Thera, Rocket Pharmaceuticals and Varda Space Industries Inc. Senior advisor to Google Ventures (GV), Blackstone, Bain & Co and Scripps Cailbr research institute.

Prior experience: Chief Scientific Officer and President of Research & Development and Medical at Pfizer. Leadership positions at Wyeth Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Pharmacia and Vimian Group AB. 

Independent of Sobi and its executive management: Yes

Independent in relation to major shareholders of Sobi: Yes

Shares in Sobi: 0.

Board member since 2025; chair of the Scientific committee; member of the Transaction committee.

Born 1960; German national.

Education: MD, PhD in internal medicine from Goethe University Frankfurt, Germany.

Other assignments: Chair of the Board of Celosia Therapeutics Pty Ltd. Board member of BioNTech SE, Financière de Tubize, Fresenius SE & Co. KGaA, Satellos Bioscience Inc. and Zealand Pharma A/S. Member of the advisory boards of Fondazione Telethon, Pierre Fabre S.A. and Helmholtz Health.

Prior experience: Executive Vice President, Chief Medical Officer and Head of Development at UCB S.A./Schwarz Pharma AG, Vice President, Head of Global Development at BASF Pharma, and various positions in clinical development at Aventis/Hoechst Marion Roussel/Hoechst AG (changed names due to mergers). 

Independent of Sobi and its executive management: Yes

Independent in relation to major shareholders of Sobi: Yes

Shares in Sobi: 1,900.

Synthetic shares: 929.
 

Board member since 2026; member of the Transaction committee.

Born 1974; Swedish national.

Education: Master of Science in Business Administration from Stockholm School of Economics, Sweden. 

Other assignments: Chair of the Board of Atlas Antibodies AB. Board member of Patricia Industries, Bonnier Group, Netcompany, Stena Adactum, Qarlbo and Internetmedicin. Lead Director at MFIN at the Stockholm School of Economics. 

Prior experience: Partner at EQT, Global Head of EQT’s Healthcare Sector, Head of Shareholder Relations and part of EQT’s Extended Executive Committee. Prior to EQT, at Texas Pacific Group and Morgan Stanley in the UK.

Independent of Sobi and its executive management: Yes

Independent in relation to major shareholders of Sobi: No

Shares in Sobi: 31,046.
 

Board member since 2020; member of the Audit committee and the Compensation & benefits committee.

Born 1969; Swedish national.

Education: Bachelor of Arts (Hons) in business administration from the London Guildhall University, UK.

Other assignments: CEO of the ESTEVE Group. Board member of Dizlin Pharmaceuticals AB and Corporacíon Químico Farmacéutical Esteve S.A.

Prior experience: More than 20 years of experience from board and executive management roles, including several senior positions within Lundbeck A/S, such as Regional Vice President for Southern and Western Europe, President and Chairman of the US operations and Global Chief Commercial Officer on Group level.

Independent of Sobi and its executive management: Yes

Independent in relation to major shareholders of Sobi: Yes

Shares in Sobi: 7,142.

Board member since 2021; chair of the Audit committee; member of the Compensation & benefits committee, and the Transaction committee.

Born 1985; Swedish national.

Education: Master of Science in economics from Stockholm School of Economics, Sweden.

Other assignments: Managing Director of Patricia Industries, part of Investor AB. Board member of Affibody Medical AB, Atlas Antibodies AB and Mölnlycke Health Care.

Prior experience: Managing Director Listed Companies, Investor AB. Chief Strategy Officer at Atlas Antibodies. Analyst at Swedbank LC&I.

Independent of Sobi and its executive management: Yes

Independent in relation to major shareholders of Sobi: No

Shares in Sobi: 2,971.

Board member, employee representative since 2023.

Born 1983; Swedish national.

Education: Bachelor of Science in Mechanical Engineering Royal Institute of Technology (KTH), Stockholm, Sweden.

Sobi position: Head of Business Control Technical Operations.

Independent of the company and its executive management: No.

Independent in relation to major shareholders of the Company: Yes. 

Shares in Sobi: 410.

Deputy for the employee representatives since 2025.

Born 1982; Swedish national.

Education: Master of Medical Science, Uppsala University, Sweden.

Sobi position: Clinical Study Manager, Clinical Study Management.

Independent of the company and its executive management: No

Independent in relation to major shareholders of the Company: Yes

Shares in Sobi: 1,585.